Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial.

Yasir Y Elamin Jacqulyne P RobichauxBrett W CarterMehmet AltanDon L GibbonsFrank V FossellaVincent K Lam Anisha B Patel Marcelo Vailati Negrão Xiuning Le Frank E Mott Jianjun ZhangLei FengGeorge BlumenscheinAnne S Tsao John Victor Heymach

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)

Poziotinib showed promising antitumor activity in patients with HER2 exon 20 mutant NSCLC including patients who had previously received platinum-based chemotherapy.

Keyphrases

wild type
small cell lung cancer
locally advanced
advanced non small cell lung cancer
open label
randomized controlled trial
squamous cell carcinoma
radiation therapy
brain metastases
tyrosine kinase